Combining a histone deacetylase inhibitor drug with immunotherapy agents is safe, and may benefit some patients with advanced cancers that have not responded to traditional therapy, according to results of a phase 1 clinical trial led by researchers
Akoya (AKYA) Announces Publication of New Immunotherapy Biomarker Signature in Science, Leveraging Principles of Astronomy and Pathology streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: The AstroPath platform allows for the assessment of the level of expression of a given marker on individual cells, while maintaining information on their spatial location. Shown here is. view more
Credit: Seyoun Park, Ph.D.
Pairing sky-mapping algorithms with advanced immunofluorescence imaging of cancer biopsies, researchers at The Mark Foundation Center for Advanced Genomics and Imaging at Johns Hopkins University and the Bloomberg~Kimmel Institute for Cancer Immunotherapy developed a robust platform to guide immunotherapy by predicting which cancers will respond to specific therapies targeting the immune system.
A new platform, called AstroPath, melds astronomic image analysis and mapping with pathology specimens to analyze microscopic images of tumors.
Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
Combination increases complete response rate to 24% compared to chemotherapy alone
Bristol Myers Squibb’s PD-1 inhibitor Opdivo has scored a new win in the pre-surgery, non-small cell lung cancer (NSCLC) setting.
Data presented at the virtual American Association for Cancer Research (AACR) annual meeting showcased results from the CheckMate-816 study, which evaluated Opdivo (nivolumab) plus chemotherapy in patients with early-stage NSCLC before surgery.
The primary endpoints of the study were pathological complete response (pCR), defined as no residual viable tumour in the resected lung specimen and the sampled lymph node after surgery and event-free survival (EFS).
Molecular biologist Erika Pearce joins Johns Hopkins as Bloomberg Distinguished Professor
A leading expert in the field of immunometabolism, she comes to the university from the Max Planck Institute of Immunology and Epigenetics
Image caption: Erika Pearce By Saralyn Cruickshank / Published April 6, 2021
Molecular biologist Erika Pearce, whose groundbreaking research into the role of metabolism in immune system regulation has led to fundamental discoveries about cellular biology and new avenues for drug development, will join Johns Hopkins University as a Bloomberg Distinguished Professor.
An international leader in the field of immunometabolism, Pearce has always had a fascination with how the body works. As a child, she was drawn to human anatomy books, spending her time scouring the pages and dreaming of becoming a doctor. But a course on basic immunology during her undergraduate studies at Cornell University sparked a love of res